Summary: Pharmacore to build a customized production line for OBI-858 botulinum toxin for Phase I and II clinical trial supply, as well as Phase III and XX after drug approval. Pharmacore estimated that the production line will be ready in 8 month; production of clinical trial supply will be ready within a year.

Limitation: The contract includes a memorandum that specifies the trade secret confidentiality and OBI’s exclusive right to use the production line.

Effect on company operations: Compare to building an in-house production line, the contract is cost effective in ways of time and manpower needs.

Objectives: To accelerate the development of OBI-858 and increase product value.